|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Global Blood Therapeutics, Inc. (GBT) |
|
|
$68.49 0.00 (0.00%) as of 4:30 Tue 10/4
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
67,460,000 |
| Market
Cap: |
4.62(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$68.49 - $68.49 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Global Blood Therapeutics is a biopharmaceutical company that engaged in the discovery, development and delivery of treatments to underserved patient communities. The U.S. Food and Drug Administration has granted approval for Co.'s Oxbryta® (voxelotor) tablets for the treatment of sickle cell disease (SCD) in adults and children 12 years of age and older. Oxbryta, an oral therapy taken once daily, is the treatment that directly inhibits sickle hemoglobin polymerization, the root cause of SCD. Co. is developing treatments for SCD, including inclacumab, a P-selectin inhibitor used to reduce the incidence of vaso-occlusive crises and hemoglobin polymerization inhibitor, GBT021601, or GBT601.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
39,287 |
| Total Sell Value |
$0 |
$0 |
$0 |
$2,538,623 |
| Total People Sold |
0 |
0 |
0 |
4 |
| Total Sell Transactions |
0 |
0 |
0 |
4 |
| End Date |
2024-03-17 |
2023-12-15 |
2023-06-16 |
2022-06-16 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Ramos Eleanor |
Chief Medical Officer |
• – – |
2016-02-01 |
4 |
A |
$16.09 |
$23,652 |
D/D |
1,470 |
12,470 |
|
- |
|
| Love Ted W |
CEO and President |
• • – |
2016-02-01 |
4 |
A |
$16.09 |
$30,973 |
D/D |
1,925 |
1,142,636 |
|
- |
|
| Radovich Peter |
See Remarks |
• – – |
2016-02-01 |
4 |
A |
$16.09 |
$19,710 |
D/D |
1,225 |
13,725 |
|
- |
|
| Schembri John |
See Remarks |
• – – |
2016-02-01 |
4 |
A |
$16.09 |
$17,602 |
D/D |
1,094 |
2,594 |
|
- |
|
| Schembri John |
See Remarks |
• – – |
2016-01-07 |
4 |
B |
$22.36 |
$22,360 |
D/D |
1,000 |
1,500 |
2.74 |
- |
|
| Schembri John |
See Remarks |
• – – |
2016-01-07 |
4 |
B |
$22.36 |
$22,360 |
D/D |
1,000 |
1,500 |
2.74 |
- |
|
| Ramos Eleanor |
Chief Medical Officer |
• – – |
2015-12-22 |
4 |
B |
$30.28 |
$30,280 |
D/D |
1,000 |
11,000 |
2.74 |
- |
|
| Choi Jung |
See Remarks |
• – – |
2015-08-17 |
4/A |
B |
$20.00 |
$500,000 |
I/I |
25,000 |
25,000 |
1.99 |
- |
|
| Ramos Eleanor |
Chief Medical Officer |
• – – |
2015-08-17 |
4/A |
B |
$20.00 |
$20,000 |
I/I |
1,000 |
1,000 |
1.99 |
- |
|
| Schembri John |
See Remarks |
• – – |
2015-08-17 |
4 |
B |
$20.00 |
$10,000 |
D/D |
500 |
500 |
2.74 |
- |
|
| Schembri John |
See Remarks |
• – – |
2015-08-17 |
4 |
B |
$20.00 |
$10,000 |
D/D |
500 |
500 |
2.74 |
- |
|
| Perry Mark L |
Director |
– • – |
2015-08-17 |
4 |
B |
$20.00 |
$100,000 |
D/D |
5,000 |
26,428 |
2.39 |
- |
|
| Love Ted W |
See Remarks |
• • – |
2015-08-17 |
4 |
B |
$20.00 |
$100,000 |
I/I |
5,000 |
2,500 |
2.66 |
- |
|
| Love Ted W |
See Remarks |
• • – |
2015-08-17 |
4 |
B |
$20.00 |
$100,000 |
D/D |
5,000 |
1,140,711 |
2.81 |
- |
|
| Choi Jung |
See Remarks |
• – – |
2015-08-17 |
4 |
B |
$20.00 |
$500,000 |
D/D |
25,000 |
167,857 |
2.74 |
- |
|
| Patrick Deval L |
Director |
– • – |
2015-08-17 |
4 |
B |
$20.00 |
$50,000 |
D/D |
2,500 |
2,500 |
2.39 |
- |
|
| Radovich Peter |
See Remarks |
• – – |
2015-08-17 |
4 |
B |
$20.00 |
$250,000 |
D/D |
12,500 |
12,500 |
2.74 |
- |
|
| Sham Hing |
SVP of Chemistry |
• – – |
2015-08-17 |
4 |
B |
$20.00 |
$40,000 |
D/D |
2,000 |
36,775 |
2.74 |
- |
|
| Ramos Eleanor |
Chief Medical Officer |
• – – |
2015-08-17 |
4 |
B |
$20.00 |
$200,000 |
D/D |
10,000 |
10,000 |
2.74 |
- |
|
| Sham Hing |
See Remarks |
• – – |
2015-08-17 |
4 |
OE |
$0.49 |
$24,311 |
D/D |
25,490 |
34,775 |
|
- |
|
| Starr Kevin P |
Director |
– • • |
2015-08-17 |
4 |
A |
$0.00 |
$0 |
I/I |
14,189,476 |
2,285,713 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2015-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
11,903,763 |
12,475,191 |
|
- |
|
| Tepper Robert I |
10% Owner |
– – • |
2015-08-17 |
4 |
A |
$0.00 |
$0 |
D/D |
2,285,713 |
2,285,713 |
|
- |
|
| Brown Willie L. Jr. |
Director |
– • – |
2015-08-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,428 |
|
- |
|
| Perry Mark L |
Director |
– • – |
2015-08-11 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
21,428 |
|
- |
|
532 Records found
|
|
Page 21 of 22 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
